The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 31, 2023

Filed:

Sep. 22, 2017
Applicant:

University of Massachusetts, Boston, MA (US);

Inventors:

Peter L. Jones, Carson City, NV (US);

Charis L. Himeda, Reno, NV (US);

Takako Jones, Carson City, NV (US);

Assignee:

University of Massachusetts, Boston, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 15/88 (2006.01); C12N 9/22 (2006.01); A61P 21/00 (2006.01); A61K 9/00 (2006.01); C12N 15/11 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
C12N 9/22 (2013.01); A61K 9/0019 (2013.01); A61P 21/00 (2018.01); C12N 15/11 (2013.01); C12N 15/907 (2013.01); C12N 2310/20 (2017.05); C12N 2750/14141 (2013.01); C12N 2800/80 (2013.01);
Abstract

The disclosure relates to methods and compositions for regulating expression of DUX4. Specifically, the disclosure provides a recombinant gene editing complex comprising: a recombinant gene editing protein; and, a nucleic acid encoding a guide RNA (gRNA) that specifically hybridizes to a target nucleic acid sequence encoding a D4Z4 macrosatellite repeat region, wherein binding of the complex to the target nucleic acid sequence results in inhibition of DUX4 gene expression. In some aspects, methods described by the disclosure are useful for treating a disease associated with aberrant DUX4 expression (e.g., facioscapulohumeral muscular dystrophy, FSHD).


Find Patent Forward Citations

Loading…